NewsBenzingaStock Market: Will S&P 500 Open Up or Down Today? Stock Market: Will S&P 500 Open Up or Down Today? Benzinga 2026.10.26 05:52 (GMT+0) Open on Benzinga Other news Reported Friday, Travere Says PROTECT Biomarker Data Add To Superior Proteinuria Reduction, Slower Kidney Function Decline Versus Irbesartan, Supporting FILSPARI As Non-Immunosuppressive, Kidney-Targeted, Foundational First-Line Treatment For IgA... Reported Saturday, Lilly Presented First Phase 1 Data For Sofe-M Plus Bevacizumab In Platinum-Sensitive Ovarian Cancer: 79% Confirmed Objective Response Rate, 100% Disease Control Rate, Activity Across FRα Expression Levels Reported Saturday, Immatics Reports IMA203CD8 Cell Therapy 51% ORR, 41% cORR Across Multiple Solid Tumors With Manageable Safety; IMA402 Bispecific Shows 32% cORR In PRAME-High Melanoma, Favorable Safety Profile Reported Saturday, Incyte To Co-Fund Genmab’s Phase 1/2 Study Of Petosemtamab Combination In First-Line KRAS G12D-Mutated Metastatic Colorectal Cancer, Provide INCB161734 Clinical Supply AstraZeneca Announced Saturday,Perioperative IMFINZI Plus Neoadjuvant Enfortumab Vedotin Cuts Recurrence Risk 49%, Death Risk 42% Versus Standard Of Care In Muscle-Invasive Bladder Cancer Patients Ineligible For Or Refusing Cisplatin, VOLGA Phase III AstraZeneca Announced Saturday, IMFINZI Plus Tarlatamab-dlle Cuts Death Risk 58% Versus IMFINZI Alone In First-Line Extensive-Stage Small Cell Lung Cancer, Median OS 21.1 Versus 12.7 Months, In DeLLphi-305 Phase III
Reported Friday, Travere Says PROTECT Biomarker Data Add To Superior Proteinuria Reduction, Slower Kidney Function Decline Versus Irbesartan, Supporting FILSPARI As Non-Immunosuppressive, Kidney-Targeted, Foundational First-Line Treatment For IgA...
Reported Saturday, Lilly Presented First Phase 1 Data For Sofe-M Plus Bevacizumab In Platinum-Sensitive Ovarian Cancer: 79% Confirmed Objective Response Rate, 100% Disease Control Rate, Activity Across FRα Expression Levels
Reported Saturday, Immatics Reports IMA203CD8 Cell Therapy 51% ORR, 41% cORR Across Multiple Solid Tumors With Manageable Safety; IMA402 Bispecific Shows 32% cORR In PRAME-High Melanoma, Favorable Safety Profile
Reported Saturday, Incyte To Co-Fund Genmab’s Phase 1/2 Study Of Petosemtamab Combination In First-Line KRAS G12D-Mutated Metastatic Colorectal Cancer, Provide INCB161734 Clinical Supply
AstraZeneca Announced Saturday,Perioperative IMFINZI Plus Neoadjuvant Enfortumab Vedotin Cuts Recurrence Risk 49%, Death Risk 42% Versus Standard Of Care In Muscle-Invasive Bladder Cancer Patients Ineligible For Or Refusing Cisplatin, VOLGA Phase III
AstraZeneca Announced Saturday, IMFINZI Plus Tarlatamab-dlle Cuts Death Risk 58% Versus IMFINZI Alone In First-Line Extensive-Stage Small Cell Lung Cancer, Median OS 21.1 Versus 12.7 Months, In DeLLphi-305 Phase III
